We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kinaxo Contributes its Quantitative Phosphoproteomics Platform to a Drug Efficiency Study
News

Kinaxo Contributes its Quantitative Phosphoproteomics Platform to a Drug Efficiency Study

Kinaxo Contributes its Quantitative Phosphoproteomics Platform to a Drug Efficiency Study
News

Kinaxo Contributes its Quantitative Phosphoproteomics Platform to a Drug Efficiency Study

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kinaxo Contributes its Quantitative Phosphoproteomics Platform to a Drug Efficiency Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kinaxo Biotechnologies GmbH announced that it was awarded a grant by the Bavarian Research Foundation to expand applications for its quantitative phosphoproteomics platform to contribute to a drug efficacy study.

Quantitative phoshpoproteomics enables analysis of the phosphoproteome, which includes all phosphorylation events occurring in a specific cell line or tissue. Since the majority of targeted small molecules used as anticancer drugs influence the cell’s signal transduction pathways, quantification of phosphorylation patterns in relation to drug administration delivers insights into a compound’s cellular mode of action.

Moreover, non-responsiveness to a multitude of compounds is a fundamental problem in cancer treatment. Here, quantitative phosphoproteomics is a powerful method to unveil the mechanisms of both cellular resistance and a drug’s effect. Furthermore, it can be a valuable tool to discover predictive biomarkers that foretell the therapeutic outcome in a patient which in turn allows a targeted therapy approach.

To develop new methods for individualized tumor therapy in pancreatic cancer, Kinaxo Biotechnologies GmbH has now joined an interdisciplinary collaboration with Priaxon AG, Genomatix Software GmbH, the Technical University Munich and the University Hospital “Rechts der Isar” to perform a large-scale drug efficiency study.
Advertisement